Supernus raises $42 million for potential epilepsy drug launches
This article was originally published in Scrip
Executive Summary
Supernus Pharmaceuticals has raised $42 million in non-dilutive funding in preparation for the launch of two product candidates in epilepsy and to further its CNS pipeline particularly in the field of attention deficit hyperactivity disorder (ADHD).